

Trying 3106016892...Open

```
Welcome to STN International! Enter x:x  
LOGINID:sssptal644axd  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2
```

\* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 Expanded CAplus Coverage of US, Japanese, WIPO,  
EPO, and German patents  
NEWS 3 Jan 18 ESBIOBASE - NEW FREE DISPLAY FORMATS, TRIAL  
FORMAT ENHANCED  
NEWS 4 Feb 1 Addition of Machine-Translated Abstracts to CAplus  
NEWS 5 Feb 2 STEREO BOND SEARCH PROBLEM FIXED WITH STN EXPRESS 5.0C  
NEWS 6 Feb 14 Homology Searching for Nucleotide Sequences in DGENE  
now available!  
NEWS 7 Feb 16 BIOTECHNOBASE NOW ON STN  
NEWS 8 Feb 22 New Database Producer Clusters Now Available on STN  
NEWS 9 Feb 28 Structure Search Limits Increased in REGISTRY,  
ZREGISTRY, and CASREACT  
NEWS 10 Feb 28 Patent Information Now Searchable in CAOLD  
NEWS 11 Mar 1 New IMS DIRECTORY Provides Pharma Company Details

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:19:38 ON 09 MAR 2000

=> file patents medline caplus biosis embase

FILE 'APIPAT2' ACCESS NOT AUTHORIZED  
FILE 'PAPERCHM' ACCESS NOT AUTHORIZED

~~FEE PAPERCHM ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS~~

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.15	0.15

FILE 'CAPLUS' ENTERED AT 09:19:59 ON 09 MAR 2000 -  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'APIPAT' ENTERED AT 09:19:59 ON 09 MAR 2000  
Abstracts copyright (C) Derwent Information Ltd.  
Remainder of the file copyright (C) 2000 Elsevier Engineering  
Information, Inc. (DERWENT/ELSEVIER)

FILE 'CROPUS' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'DGENE' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'DPCI' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'EUROPATFULL' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'IFIPAT' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 IFI CLAIMS(R) Patent Services (IFI)

FILE 'INPADOC' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 European Patent Office, Vienna (EPO)

FILE 'JAPIO' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'PAPERCHEM2' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 Institute of Paper Science and Technology (IPST)

FILE 'PATDD' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT 2000 (C) Deutsches Patent- und Markenamt (DPMA)

FILE 'PATDPA' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (c) 2000 Deutsches Patent- und Markenamt / FIZ Karlsruhe (DPMA/FIZ KA)

FILE 'PATOSDE' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PATOSEP' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PATOSWO' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PIRA' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 Pira International

FILE 'RAPRA' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 RAPRA Technology Ltd.

FILE 'TULSA' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 The University of Tulsa (UTULSA)

FILE 'USPATFULL' ENTERED AT 09:19:59 ON 09 MAR 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'MEDLINE' ENTERED AT 09:19:59 ON 09 MAR 2000

FILE 'BIOSIS' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 09:19:59 ON 09 MAR 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

=> s HF (1N) COLL (1N) 18?

TERM '18?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED  
COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.  
Enter "HELP STN" for information on contacting the nearest STN Help  
Desk by telephone or via SEND in the STNMAIL file.

=> s HF (1N) COLL? or HF?COLL?18?514cf

'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'  
The truncation symbol ? may be used only at the end of a search  
term. To specify a variable character within a word use '!', e.g.,  
'wom!n' to search for both 'woman' and 'women'. Enter "HELP  
TRUNCATION" at an arrow prompt (=>) for more information.

=> s HF (1N) COLL? or HFCOLL?

6 FILES SEARCHED...  
15 FILES SEARCHED...  
L1 247 HF (1N) COLL? OR HFCOLL?

=> dis 11 (P) fragment

'(P)' IS NOT A VALID FORMAT  
'FRAGMENT' IS NOT A VALID FORMAT  
In a multifile environment, a format can only be used if it is valid  
in at least one of the files. Refer to file specific help messages  
or the STNGUIDE file for information on formats available in  
individual files.  
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> s 11 (P) fragment

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'L2 (P) FRAGMENT'  
15 FILES SEARCHED...  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L17 (P) FRAGMENT'  
L2 12 L1 (P) FRAGMENT

=> duplicate remove 12 1-12

DUPLICATE IS NOT AVAILABLE IN 'DGENE, DPCI'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
'1-12' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS, DGENE, EUROPATFULL,  
INPADOC, PATOSEP, PATOSWO, USPATFULL'  
You have entered a file name of duplicates to keep that is not  
referenced by any of the L#s specified for this DUPLICATE command.  
The file names of duplicates that can be kept are listed above.  
Please enter one of these file names.  
ENTER FILE NAMES OF DUPLICATES TO KEEP:end

=> duplicate remove 12

DUPLICATE IS NOT AVAILABLE IN 'DGENE, DPCI'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
DUPLICATE PREFERENCE IS 'CAPLUS, DGENE, EUROPATFULL, INPADOC, PATOSEP,  
PATOSWO, USPATFULL'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L2  
L3 10 DUPLICATE REMOVE L2 (2 DUPLICATES REMOVED)

=> dis 13 1-10 kwic

L3 ANSWER 1 OF 10 INPADOC COPYRIGHT 2000 EPO  
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT HF-COLL-18/514CF**) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS  
  
L3 ANSWER 2 OF 10 INPADOC COPYRIGHT 2000 EPO  
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT HF-COLL-18/514CF**) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS  
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT HF-COLL-18/514CF**) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS  
  
L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS  
TI **Collagen fragment HF-COLL-18/514cf**  
from body fluids for influencing cell growth and diagnosis of collagen diseases and osteoporosis  
AB **Collagen fragment HF-COLL-18/514cf**, with the N-terminal sequence Val-Ala-Arg-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu, was obtained from human hemofiltrate and purified by cation-exchange chromatog. and preparative reversed-phase chromatog. on a PrepPak cartridge. The **fragment** (mol. wt. 18,493) or antibodies to it are useful for treatment or diagnosis of connective tissue, respiratory, urogenital, circulatory, nervous, . . .  
IT Antosteoporotic agents  
Cardiovascular diseases  
Connective tissue diseases  
Immunoassay  
Immunodiagnosis  
Infusions (drug delivery systems)  
Nervous system diseases

Protein sequences  
Respiratory tract diseases  
Skin diseases  
Tooth diseases  
    (**collagen fragment HF-COLL**  
    -18/514cf from body fluids for influencing cell growth and diagnosis  
of  
    collagen diseases and osteoporosis)  
IT Antibodies  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
    (**collagen fragment HF-COLL**  
    -18/514cf from body fluids for influencing cell growth and diagnosis  
of  
    collagen diseases and osteoporosis)  
IT Blood proteins  
RL: BAC (Biological activity or effector, except adverse); BPR  
(Biological  
process); PRP (Properties); PUR (Purification or recovery); SPN  
(Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); PROC (Process); USES (Uses)  
    (**collagen fragment HF-COLL**  
    -18/514cf; **collagen fragment HF-**  
**COLL**-18/514cf from body fluids for influencing cell growth and  
diagnosis of collagen diseases and osteoporosis)  
IT Urogenital tract  
    (diseases; **collagen fragment HF-**  
**COLL**-18/514cf from body fluids for influencing cell growth and  
diagnosis of collagen diseases and osteoporosis)  
IT Genes (animal)  
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
    (for **collagen fragment HF-COLL**  
    -18/514cf of human, expression of; **collagen fragment**  
**HF-COLL**-18/514cf from body fluids for influencing  
cell growth and diagnosis of collagen diseases and osteoporosis)  
IT Peptides, biological studies  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
    (of **collagen fragment HF-COLL**  
    -18/514cf; **collagen fragment HF-**  
**COLL**-18/514cf from body fluids for influencing cell growth and  
diagnosis of collagen diseases and osteoporosis)  
IT Organ (animal)  
    (sensory, diseases; **collagen fragment HF-**  
**COLL**-18/514cf from body fluids for influencing cell growth and  
diagnosis of collagen diseases and osteoporosis)  
IT 198403-05-3P  
RL: BAC (Biological activity or effector, except adverse); BPR  
(Biological  
process); PRP (Properties); PUR (Purification or recovery); SPN  
(Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); PROC (Process); USES (Uses)  
    (**collagen fragment HF-COLL**  
    -18/514cf from body fluids for influencing cell growth and diagnosis  
of  
    collagen diseases and osteoporosis)

L3 ANSWER 4 OF 10 EUROPATFULL COPYRIGHT 2000 WILA  
DETDEN Fibroblasts were released from dermal **fragments** by digesting  
these with Clostridium histolyticum **collagenase**. **HFs**  
were then grown in DMEM using standard methods.

L3 ANSWER 5 OF 10 INPADOC COPYRIGHT 2000 EPO

TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT  
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS  
AND CAPILLARY PROFILERATIONS

L3 ANSWER 6 OF 10 USPATFULL

DETD Fibroblasts were released from dermal **fragments** by digesting these with Clostridium histolyticum **collagenase**. **HF**s were then grown in DMEM using standard methods.

L3 ANSWER 7 OF 10 USPATFULL

DETD Fibroblasts were released from dermal **fragments** by digesting these with Clostridium histolyticum **collagenase**. **HF**s were then grown in DMEM using standard methods.

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB . . . (8 keV) collision-induced dissociation (CID) experiments performed with a double-focusing quadrupole hybrid mass spectrometer. The 2-fluoro- and 3-fluorophenyl anions eliminate **HF** following **collision** with an oxygen mol. By contrast, the collisions between 4-fluorophenyl anions and O<sub>2</sub> do not yield detectable amounts of neg. charged **fragment** ions owing to the exclusive occurrence of electron detachment. Electron detachment is also the only process observed in the 8.

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2000 ACS

AB . . . 34 kcal/mol at a rather stretched nuclear geometry, is in qual. agreement with an ab initio surface for the analogous **collinear** Be + **HF** system. Reaction pathways and reactant-to-product correlation diagrams are also discussed. A simple estn. of the sensitivity of the most prominent features of the calcd. potential energy surfaces to the input diat. **fragment** data demonstrates that these features cannot be attributed to errors made in those data.

L3 ANSWER 10 OF 10 DGENE COPYRIGHT 2000 DERWENT INFORMATION LTD

AB This is the N-terminal amino acid sequence of a novel protein **HF-COLL-18/514cf**. Medicaments containing **HF-COLL-18/514cf** or its derivatives or **fragments** are useful for treating human diseases, especially involving supporting or connective tissue, the respiratory or urogenital tract, the cardiovascular or . . . the integuments or the sense organs. The medicaments are also used for treating systemic diseases with overproduction or deficiency of **HF-COLL-18/514cf**, especially with e.g. use of antibodies raised against this or **HF-COLL-18/514cf** for substitution therapy. The protein, in a suitable form, can also be used to treat chronic diseases involving electrolyte action. . . or at the dental apparatus. The protein is also used for diagnosis of diseases by producing specific antibodies against synthetic **fragments** or the entire peptide or its derivatives and its **fragments** and measuring the blood concentration of **HF-COLL-18/514cf** via an immunoassay

=> dis 13 1-10

L3 ANSWER 1 OF 10 INPADOC COPYRIGHT 2000 EPO DUPLICATE 1

LEVEL 1

AN 27248995 INPADOC EW 199907 UP 19991124 UW 199946

TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT  
**HF-COLL-18/514CF**) FOR INHIBITING THE GROWTH OF TUMOURS  
AND CAPILLARY PROFILERATIONS

IN FORSSMANN, WOLF-GEORG, PROF.DR.MED.; SCHRADER, MICHAEL; STAENDKER,  
LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER

INS FORSSMANN WOLF-GEORG PROF DR M; SCHRADER MICHAEL; STAENDKER LUDGER;  
RAIDA

MANFRED; SCHULZ-KNAPPE PETER  
INA DE; DE; DE; DE; DE  
PA HAEMOPEP PHARMA GMBH; BIOVISION GMBH & CO. KG  
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG  
PAA DE; DE  
TL English; French; German  
LA German  
DT Patent  
PIT EPA2 PUBL. OF APPLICATION WITHOUT SEARCH REPORT  
PI EP 896584 A2 19990217  
DS R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
AI EP 1997-921682 A 19970422  
PRAI DE 1996-19615710 A 19960422  
WO 1997-EP2012 W 19970422

L3 ANSWER 2 OF 10 INPADOC COPYRIGHT 2000 EPO DUPLICATE 2

LEVEL 1

AN 42485223 INPADOC UW 199805  
TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT  
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS  
AND CAPILLARY PROFILERATIONS  
IN FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL; STAENDKER, LUDGER; RAIDA,  
MANFRED; SCHULZ-KNAPPE, PETER  
INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STAENDKER LUDGER; RAIDA MANFRED;  
SCHULZ-KNAPPE PETER  
INA DE; DE; DE; DE  
PA HAEMOPEP PHARMA GMBH; FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL;  
STAENDKER, LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER  
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG; SCHRADER MICHAEL; STAENDKER  
LUDGER; RAIDA MANFRED; SCHULZ KNAPPE PETER  
PAA DE; DE; DE; DE; DE  
TL English; French; German  
LA German  
DT Patent  
PIT WOA2 PUBL. OF THE INT.APPL. WITHOUT INT.SEARCH REP.  
PI WO 9740073 A2 19971030  
DS RW: GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG  
W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR  
LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY  
KG KZ MD RU TJ TM  
AI WO 1997-EP2012 A 19970422  
PRAI DE 1996-19615710 A 19960422

LEVEL 2

AN 42485223 INPADOC EW 199804 UW 199804  
TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT  
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS  
AND CAPILLARY PROFILERATIONS  
IN FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL; STAENDKER, LUDGER; RAIDA,  
MANFRED; SCHULZ-KNAPPE, PETER  
INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STAENDKER LUDGER; RAIDA MANFRED;  
SCHULZ-KNAPPE PETER  
INA DE; DE; DE; DE  
PA HAEMOPEP PHARMA GMBH; FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL;  
STAENDKER, LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER  
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG; SCHRADER MICHAEL; STAENDKER  
LUDGER; RAIDA MANFRED; SCHULZ KNAPPE PETER  
PAA DE; DE; DE; DE; DE  
TL English; French; German  
LA German  
DT Patent  
PIT WOA3 SUBSEQUENT PUBL. OF THE INT. SEARCH REPORT  
PI WO 9740073 A3 19971224

DS RW: GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT  
 SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG  
 W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR  
 LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY  
 KG KZ MD RU TJ TM  
 AI WO 1997-EP2012 A 19970422  
 PRAI DE 1996-19615710 A 19960422

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS  
 AN 1997:711835 CAPLUS  
 DN 127:351169  
 TI Collagen fragment HF-COLL-18/514cf  
 from body fluids for influencing cell growth and diagnosis of collagen  
 diseases and osteoporosis  
 IN Schrader, Michael; Forssmann, Wolf-Georg; Raida, Manfred; Schulz-Knappe,  
 Peter  
 PA Forssmann, Wolf-Georg, Germany  
 SO Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19615710	A1	19971023	DE 1996-19615710	19960422
	WO 9740073	A2	19971030	WO 1997-EP2012	19970422
	WO 9740073	A3	19971224		
		W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
		RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	AU 9727665	A1	19971112	AU 1997-27665	19970422
	EP 896584	A2	19990217	EP 1997-921682	19970422
		R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
PRAI	DE 1996-19615710		19960422		
	WO 1997-EP2012		19970422		

L3 ANSWER 4 OF 10 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 526550 EUROPATFULL ED 19980112 EW 199752 FS PS  
 TIEN COMPOSITE LIVING SKIN EQUIVALENTS.  
 TIDE ZUSAMMENGESETZTES AeQUIVALENT DER LEBENDEN HAUT.  
 TIFR EQUIVALENTS COMPOSITES DE PEAU VIVANTE.  
 IN EISENBERG, Mark, 6 Lord Howe Street, Dower Heights, NSW 2030, AU  
 PA EISENBERG, Mark, 6 Lord Howe Street, Dower Heights, NSW 2030, AU  
 SO Wila-EPS-1997-H52-T2  
 DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU;  
 R NL; R SE  
 PIT EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)  
 PI EP 526550 B1 19971229  
 OD 19930210  
 AI EP 1991-908747 19910424  
 PRAI AU 1990-9819 19900424  
 AU 1991-4302 19910122  
 RLI WO 91-AU160 910424 INTAKZ  
 WO 9116010 911031 INTPNR  
 REP EP 243132 A WO 86-02273 A  
 WO 88-08305 A AU 1374288 A  
 AU 1374388 A US 4485096 A

REN BELL. E. et al. (1983): "The Reconstruction of Living Skin, The Journal of Investigative Dermatology", Volume 81, No. 1, Supplement pages 2-10. (see pages 1 and 5 in particular) DYKES, P.J. et al. (1991): "In Vitro Reconstruction of Human Skin: The Use of Skin Equivalents as Potential Indicators of Cutaneous Toxicity, Toxicology In Vitro", Volume 5, No.

1,

pages 1-8 (see introduction and discussion in particular) ROWLING, P.J.E. et al. (1990): "Fabrication and Reorganization of Dermal Equivalents Suitable for Skin Grafting after Major Cutaneous Injury, Biomaterials", Volume 11, pages 181-185; published April 1990

IC ICM A61F002-10

ICS A61L027-00 C12N005-08 C12N005-00

L3 ANSWER 5 OF 10 INPADOC COPYRIGHT 2000 EPO

LEVEL 1

AN 46467201 INPADOC EW 199807 UW 199807

TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT

HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS  
AND CAPILLARY PROFILERATIONS

IN WOLF-GEORG FORSSMANN; MICHAEL SCHRADER; LUDGER STANDKER; MANFRED RAIDA;  
PETER SCHULZ-KNAPPE

INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STANDKER LUDGER; RAIDA MANFRED;  
SCHULZ-KNAPPE PETER

PA WOLF-GEORG FORSSMANN; HAEMOPEP PHARMA GMBH

PAS WOLF GEORG FORSSMANN; HAEMOPEP PHARMA GMBH

DT Patent

PIT AUAI COMP. SPEC. OPEN TO PUB. INSP.

PI AU 9727665 A1 19971112

AI AU 1997-27665 A 19970422

PRAI DE 1996-19615710 A 19960422

WO 1997-EP2012 W 19970422

L3 ANSWER 6 OF 10 USPATFULL

AN 96:112621 USPATFULL

TI Composite living skin equivalents

IN Eisenberg, Mark, 6 Lord Howe Street, Dover Heights, NSW 2030, Australia

PI US 35399 19961210

US 5282859 19940201 (Original)

WO 9116010 19911031

AI US 1994-346525 19941129 (8)

US 1991-777419 19911127 (Original)

WO 1991-AU160 19910424

19911127 PCT 371 date

19911127 PCT 102(e) date

PRAI AU 1990-9819 19900424

AU 1991-4302 19910122

DT Reissue

LN.CNT 652

INCL INCLM: 623/011.000

INCLS: 623/015.000; 623/066.000; 128/DIG.008; 435/240.240; 424/424.000;  
602/042.000

NCL NCLM: 623/011.000

NCLS: 128/DIG.008; 424/424.000; 602/042.000; 623/015.000; 623/066.000

IC [6]

ICM: A61F002-02

ICS: A61F002-10; A61F002-00; C12N005-00

EXF 623/1; 623/2; 623/11; 623/12; 623/66; 435/240.24; 435/240.241; 424/424;  
602/42; 128/DIG.8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 10 USPATFULL

AN 94:9198 USPATFULL

TI Composite living skin equivalents

IN Eisenberg, Mark, 6 Lord Howe Street, Dover Heights, NSW 2030, Australia

PI US 5282859 19940201  
WO 9116010 19911031  
AI US 1991-777419 19911127 (7)  
WO 1991-AU160 19910424  
19911127 PCT 371 date  
19911127 PCT 102(e) date  
PRAI AU 1990-9819 19900424  
AU 1991-4302 19910122  
DT Utility  
LN.CNT 598  
INCL INCLM: 623/011.000  
INCLS: 623/015.000; 623/066.000; 128/DIG.008; 435/240.241; 424/424.000;  
602/042.000  
NCL NCLM: 623/011.000  
NCLS: 128/DIG.008; 424/424.000; 435/371.000; 435/398.000; 602/042.000;  
623/015.000; 623/066.000  
IC [5]  
ICM: A61F002-02  
ICS: A61F002-10; A61F002-00; C12N005-00  
EXF 623/11; 623/66; 623/15; 424/422; 424/423; 424/424; 128/DIG.8; 602/41;  
602/42; 602/43; 602/48; 435/240.241; 435/283  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS  
AN 1994:30378 CAPLUS  
DN 120:30378  
TI Collision-induced dissociation and charge-reversal processes of isomeric C<sub>6</sub>H<sub>4</sub>X- (X = F, Cl and Br) anions  
AU Tomperi, Paivi H.; Matimba, Henri E. K.; Ingemann, Steen; Nibbering, Nico M. M.  
CS Inst. Mass Spectrom., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.  
SO Rapid Commun. Mass Spectrom. (1993), 7(8), 749-56  
CODEN: RCMSEF; ISSN: 0951-4198  
DT Journal  
LA English

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2000 ACS  
AN 1980:573921 CAPLUS  
DN 93:173921  
TI Valence bond diatomics-in-molecules (DIM) treatment of collinear interactions of Group IIa and IIb metal atoms with hydrogen halides: application to the calcium hydrogen chloride system  
AU Isaacson, Alan D.; Muckerman, James T.  
CS Chem. Dep., Brookhaven Natl. Lab., Upton, NY, 11973, USA  
SO J. Chem. Phys. (1980), 73(4), 1739-49  
CODEN: JCPSA6; ISSN: 0021-9606  
DT Journal  
LA English

L3 ANSWER 10 OF 10 DGENE COPYRIGHT 2000 DERWENT INFORMATION LTD  
AN 1997P-W44651 peptide DGENE  
TI Protein HF-COLL-18/514cf - useful for treating, e.g. diseases of supporting or connective tissue, respiratory or urogenital tract or of the cardiovascular or nervous system  
IN Forssmann W; Raida M; Schrader M; Schulz-knappe P  
PA (EORS-I) FORSSMANN W  
PI DE 19615710 A1 19971023 6p  
AI DE 1996-19615710 19960422  
PRAI DE 1996-19615710 19960422  
DT Patent  
LA German  
OS 1997-514492 [48]

*Applicant*